You Are More Bacteria Than Human — And Microbiome Medicine Will Be Mainstream by 2035

The Question

You have probably heard that your body contains ten times more bacteria than human cells. It is a great line. It is also wrong. When scientists Ron Sender, Shai Fuchs, and Ron Milo actually did the arithmetic in 2016, the real ratio turned out to be far more modest — and far stranger for being true. A typical adult carries about 38 trillion bacterial cells and about 30 trillion human cells. Not ten to one. Roughly one to one, tipped just slightly toward the bacteria.

Sit with that honestly stated fact. By the number of living cells, you are a near-even partnership between your own tissue and a vast crowd of microbes — most of them packed into your gut. For most of medical history, doctors treated those microbes as either irrelevant or as germs to be killed. Now researchers are asking a different question: if half of you is microbial, and that half talks constantly to your immune system, your digestion, and your brain, should medicine start treating the microbes as part of the patient? The evidence increasingly says yes.

What the Evidence Shows

The strongest proof that the microbiome is medicine, not mysticism, comes from a nasty infection called C. difficile. It strikes when antibiotics wipe out the gut's normal bacteria and one aggressive species takes over, causing severe, sometimes deadly diarrhoea that ordinary drugs struggle to cure. The fix sounds crude and works astonishingly well: a faecal microbiota transplant — transferring screened stool from a healthy donor to restock the patient's gut. Clinical studies report cure rates around 90%, and in 2022 and 2023 regulators approved the first microbiome-based therapies built on exactly this principle. That is the honest headline: for one disease, resetting the microbiome is now an approved, high-success treatment.

Beyond that solid ground, the science is promising but younger. The gut community has been repeatedly linked to how well the immune system works, to inflammatory bowel conditions, to how patients respond to certain cancer drugs, and — through what researchers call the gut-brain axis, the two-way chemical conversation between the intestines and the nervous system — even to mood and anxiety. It is crucial to be precise here: many of these are associations and early trials, not settled cures. The microbiome is not yet a magic dial for every illness, and honest scientists say so.

What is turning this from research into medicine is falling cost. Sequencing the DNA of an entire microbial community — reading which species live in a gut and in what proportions — has plunged in price, the same way human genome sequencing did. A test that once cost a fortune and took a lab weeks is heading toward something a clinic could order routinely. Once doctors can cheaply see your microbial makeup and compare it against thousands of others, the microbiome stops being an abstract idea and becomes a measurable, trackable, treatable thing — a new organ we can finally read.

Why This Is Happening

One clear success has opened the door for the rest. Faecal transplants for C. difficile proved, beyond argument, that manipulating the microbiome can cure a real disease at scale. That single, undeniable win gave regulators a template, gave investors confidence, and gave the whole field credibility it lacked when it was mostly promising mouse studies. Medicine tends to move once it has one solid foothold — and it now has one.

The reading technology got cheap at the right moment. Understanding the microbiome was impossible while identifying its members cost too much. Plunging DNA-sequencing prices changed that overnight in historical terms. When a diagnostic becomes affordable, it spreads from research labs into ordinary clinics fast — exactly the path that genetic testing took over the past two decades.

The commercial and patient pull is enormous. Conditions tied to the gut — digestive disease, obesity, immune disorders — affect billions and cost health systems fortunes. That creates powerful incentives for drug companies, diagnostics firms, and food makers to invest, while patients frustrated by conditions conventional medicine handles poorly are eager for new options. Demand and money together push a field forward faster than curiosity alone ever could.

What Could Happen

What Can We Do

You do not need to wait for 2035 to tend your microbial half — and a little skepticism will protect you while the science matures.

Feed the garden with fibre and variety, not hype. The best-supported way to nurture a healthy gut community is unglamorous: eat a wide range of plants, plenty of fibre, and some fermented foods. This is cheap, safe, and backed by far stronger evidence than most supplements. Start with your plate before you reach for a pill.

Treat antibiotics with respect. Antibiotics save lives, but each course also clears out beneficial microbes — the very disruption that lets infections like C. difficile take hold. Take them when a doctor says you need them, finish the course, and never demand them for viral illnesses like colds, where they do nothing but damage your gut.

Be wary of microbiome kits that promise the world. Direct-to-consumer gut tests vary wildly in quality, and many sell confident "personalised" advice the science cannot yet support. If a product claims to fix your mood, weight, or immunity from a stool sample, treat that as a warning sign. Ask whether a claim comes from a clinical trial or a marketing team.

Raise it with a real doctor, especially for gut disease. If you have a persistent digestive or immune condition, ask your physician what the current, evidence-based microbiome options are. For approved uses like recurrent C. difficile, the treatments are genuine and powerful. A qualified clinician is your best filter between what works today and what is still just a promising headline.